Key result
Lipoprotein(a) levels showed no significant correlation with baseline infarct size or medium-term major adverse cardiovascular events in patients with STEMI.
Why the study?
The impact of lipoprotein(a) on ischemic myocardial injury and ischemia–reperfusion injury patterns in STEMI patients remains unclear.
Does elevated lipoprotein(a) increase myocardial infarct size or microvascular injury in patients with ST-elevation myocardial infarction?
Cohort (n=518)
No
Does elevated lipoprotein(a) increase myocardial infarct size or microvascular injury in patients with ST-elevation myocardial infarction?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Lipoprotein(a) should primarily be regarded as a risk-enhancing factor for the development of cardiovascular events, the authors conclude, rather than as a marker of infarct severity once STEMI has occurred.”
Despite being an established long-term cardiovascular risk factor, lipoprotein(a) does not appear to correlate with the acute severity of myocardial ischemia-reperfusion injury in STEMI patients.
Background Hypercholesterolemia adversely affects ischemia–reperfusion injury in acute ST-elevation myocardial infarction (STEMI). Lipoprotein(a) (Lp(a)) is an independent cardiovascular risk factor beyond traditional lipid markers; however, its impact on ischemic myocardial injury remains unclear. We therefore investigated the association of Lp(a) with myocardial and microvascular damage assessed by multiparametric cardiovascular magnetic resonance (CMR), as well as clinical outcomes in STEMI patients. Methods and Results In this prospective MARINA-STEMI (NCT04113356) cohort study, 518 STEMI patients (median age 59 years, 19% female) treated with primary percutaneous coronary intervention (PCI) were included. Lp(a) and lipid parameters, including low-density lipoprotein (LDL) cholesterol, were measured at hospital admission. CMR was performed at a median of 4 days (interquartile range (IQR) 3–5) and 4 months (IQR 4–5) after PCI. The primary objective was to assess the association of Lp(a) with infarct size (IS) and severe microvascular injury, defined as intramyocardial hemorrhage (IMH) on baseline CMR. The clinical endpoint was major adverse cardiovascular events (MACE: all-cause death, re-infarction, or new congestive heart failure). Median Lp(a) and LDL cholesterol levels were 27 nmol/l (IQR 20–90) and 141 mg/dl (IQR 117–166), respectively. LDL cholesterol correlated with IS at baseline ( ρ = 0.114, p = 0.010) and was higher in patients with IMH (145 vs. 140 mg/dl, p = 0.031). In contrast, Lp(a) showed no correlation with IS ( ρ = 0.051, p = 0.246) and no association with IMH (25 vs. 28 nmol/l, p = 0.632). Elevated Lp(a) (≥ 105 nmol/l) was not associated with MACE (8.7% vs. 8.8%, p = 0.966). Conclusions While LDL cholesterol was significantly associated with IS and IMH, Lp(a) was not related to ischemia–reperfusion injury patterns or clinical outcomes in patients with STEMI treated with primary PCI. Graphical abstract "Image missing" Created in https://BioRender.com MACE: composite of all-cause death, myocardial re-infarction and new congestive heart failure after discharge for the index event. Lp(a) concentrations ≥ 105 nmol/l are considered elevated according to current guidelines [1]. CMR = cardiovascular magnetic resonance; IMH = intramyocardial hemorrhage; IS = infarct size; LDL = low-density lipoprotein cholesterol; Lp(a) = lipoprotein(a); LVMM = left ventricular myocardial mass; MACE = major adverse cardiovascular events; pPCI = primary percutaneous coronary intervention; STEMI = ST-elevation myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Holzknecht et al. (2026) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=518). Lipoprotein(a) vs. Lower Lipoprotein(a) levels (< 105 nmol/l) was evaluated on Infarct size (IS) as a percentage of left ventricular myocardial mass on baseline CMR (OR 1.28, 95% CI 0.84-1.94, p=0.251). Lipoprotein(a) levels showed no significant correlation with baseline infarct size or medium-term major adverse cardiovascular events in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: